Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
ESSENTIAL JOB FUNCTIONS:
The Senior Director of Investor Relations will be responsible for constantly evolving and executing the investor relations and corporate communications strategy to effectively communicate the company’s business model, financial performance, and growth strategy to the investment community. This role will serve as a key liaison between the company and its investors, analysts, and other stakeholders.
- Support the CEO and other Senior Leaders in the development and execution of a comprehensive investor relations strategy tailored to Kura’s portfolio, stage of development, milestones, and trajectory
- Prepare and present financial and operational updates to investors, analysts and other stakeholders
- Serve as a key point of contact for investors, sell-side analysts, and other members of the investment community, supporting the CEO in providing timely and accurate information about Kura’s programs, pipeline, and milestones
- Lead the planning and execution of investor conferences, earnings calls, roadshows, and other investor engagements
- Collaborate with cross functional teams to drive the development of key messages and impactful materials and presentations for investors that are aligned with key messages (e.g., press releases, quarterly reports, conference call scripts, slide presentations, and Q&A documents) to be used by senior management for investor events including one-on-one meetings, non-deal roadshows, and investor conferences
- Oversee corporate communications, ensuring that all external messaging is cohesive and accurately reflects the company’s financial and operational performance.
- Develop strategic targeting analyses and meeting prioritization; track all company interactions; analyze and monitor the company’s shareholder base
- Lead coordination of investor relations conference calendar and help drive an active IR calendar to support the communication of Kura’s strategy and key milestones to investors
- Analyze economic and sector updates, analyst research, investor sentiment, and competitor activity to deliver actionable insights to the executive leadership team
JOB SPECIFICATIONS:
- Bachelor’s degree in finance, business, or related field; MBA or advanced degree preferred
- Minimum of 10 years of experience in investor relations, finance, or corporate communications
- Demonstrated experience in a leadership role, with a proven ability to manage and develop team members effectively
- Experience in a biopharma organization required
- In-depth understanding of the biotech/pharma landscape, including regulatory, clinical, and commercial dynamics
- Demonstrated ability to establish and maintain relationships with the biotechnology investment community
- Proven track record of effectively managing investor relations at a publicly traded biotech or pharmaceutical company.
- Strong understanding of financial statements, valuation methodologies, and capital markets dynamics.
- Exceptional communication skills, with the ability to translate complex scientific and financial data into compelling investor messaging.
- Established relationships with institutional investors, sell-side analysts, and financial media.
The base range for a Senior Director is $246,482 - $290,189 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
What We Do
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial.
For additional information, please visit our website at www.kuraoncology.com.
